Manuel Comabella

List of Publications by Year
in descending order

238 papers	16,009 citations	26630 56 h-index	19190 118 g-index
248 all docs	248 docs citations	248 times ranked	19115 citing authors

#	Article	IF	Citations
1	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	3.0	10
2	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	3.6	10
3	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	3.0	7
4	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	3.6	5
5	Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis. Human Molecular Genetics, 2022, 31, 2155-2163.	2.9	4
6	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1143.	6.0	17
7	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 732-740.	1.9	8
8	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	3.0	11
9	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving nonâ€cellâ€autonomous neuronal damage. Clinical and Translational Medicine, 2022, 12, e837.	4.0	4
10	Multiple sclerosis: Immunopathological heterogeneity and its implications. European Journal of Immunology, 2022, 52, 869-881.	2.9	3
11	Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	35
12	COVIDâ€19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. European Journal of Neurology, 2021, 28, 3384-3395.	3.3	111
13	CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	19
14	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Multiple Sclerosis Journal, 2021, 27, 913-921.	3.0	20
15	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	12
16	Angiogenin in the Neurogenic Subventricular Zone After Stroke. Frontiers in Neurology, 2021, 12, 662235.	2.4	5
17	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 685139.	4.8	13
18	Targeting Inflammasomes to Treat Neurological Diseases. Annals of Neurology, 2021, 90, 177-188.	5.3	46

#	Article	IF	Citations
19	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1065.	6.0	1
20	CSF Chitinase 3â€“Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
21	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.1	35
22	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.1	32
23	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. Frontiers in Immunology, 2021, 12, 760546.	4.8	3
24	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55â€“IL6ST Gene Region in Immature Dendritic Cells. Frontiers in Immunology, 2021, 12, 816930.	4.8	6
25	Immunomodulatory Effects Associated with Cladribine Treatment. Cells, 2021, 10, 3488.	4.1	14
26	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	3.0	52
27	A pharmacogenetic study implicates NINJ2 in the response to Interferon-Î² in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	3.0	5
28	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Multiple Sclerosis Journal, 2020, 26, 1658-1669.	3.0	41
29	The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. Multiple Sclerosis Journal, 2020, 26, 1329-1339.	3.0	23
30	Modelling multiple sclerosis using induced pluripotent stem cells. Journal of Neuroimmunology, 2020, 349, 577425.	2.3	7
31	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Frontiers in Neurology, 2020, 11, 579438.	2.4	9
32	Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 2020, 95, 436-444.	1.1	100
33	Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852098014.	3.0	3
34	Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. Epigenomics, 2020, 12, 2065-2076.	2.1	12
35	A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 771.	4.8	4
36	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Human Mutation, 2020, 41, 1308-1320.	2.5	1

#	Article	IF	Citations
37	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. Journal of Clinical Medicine, 2020, 9, 625.	2.4	5
38	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. Cells, 2020, 9, 175.	4.1	1
39	Chitinase 3-like 1 is neurotoxic in primary cultured neurons. Scientific Reports, 2020, 10, 7118.	3.3	27
40	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain, 2020, 143, 1414-1430.	7.6	92
41	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
42	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1535-1538.	3.0	5
43	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	12.6	710
44	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2019, 92, e1507-e1516.	1.1	49
45	Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology, 2019, 92, 296-298.	1.1	15
46	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	2.3	22
47	Biomarkers in Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a029058.	6.2	88
48	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain, 2018, 141, 1075-1084.	7.6	98
49	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
50	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
51	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Multiple Sclerosis Journal, 2018, 24, 301-312.	3.0	79
52	Disability progression markers over 6â€“12â€‰years in interferon-Î²-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 322-330.	3.0	60
53	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1507-1510.	3.0	11
54	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 67-84.	1.8	39

#	Article	IF	Citations
55	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1362-1371.	3.7	20
56	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. Journal of Neuroinflammation, 2018, 15, 296.	7.2	7
57	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
58	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. Journal of Neuroinflammation, 2018, 15, 265.	7.2	25
59	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	10.1	1,177
60	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3â€like 1 and neurofilament light chain. European Journal of Neurology, 2018, 25, 1189-1191.	3.3	53
61	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics Journal, 2017, 17, 312-318.	2.0	28
62	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. Journal of Neuroimmunology, 2017, 303, 62-65.	2.3	16
63	Metabolomic signatures associated with disease severity in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e321.	6.0	89
64	B cells and variant BAFF in autoimmune disease. Nature Reviews Neurology, 2017, 13, 453-454.	10.1	2
65	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
66	Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. Scientific Reports, 2017, 7, 13544.	3.3	10
67	Reply. Annals of Neurology, 2017, 82, 647-648.	5.3	0
68	Matrix metalloproteinase 9 is decreased in natalizumabâ€treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Annals of Neurology, 2017, 82, 186-195.	5.3	14
69	Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. Stem Cell Research, 2017, 24, 155-159.	0.7	10
70	Lesion topographies in multiple sclerosis diagnosis. Neurology, 2017, 89, 2351-2356.	1.1	27
71	Decreased soluble IFN-Î² receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. Multiple Sclerosis Journal, 2017, 23, 937-945.	3.0	12
72	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12, e0170395.	2.5	34

#	Article	IF	Citations
73	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
74	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3: Genes, Genomes, Genetics, 2016, 6, 2073-2079.	1.8	13
75	Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. Journal of Immunology, 2016, 196, 4553-4565.	0.8	21
76	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.1	85
77	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. Multiple Sclerosis Journal, 2016, 22, 18-33.	3.0	20
78	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology, 2016, 87, 1368-1374.	1.1	42
79	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494.	1.1	18
80	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	8.1	24
81	Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	3
82	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36
83	Precision medicine in multiple sclerosis. Current Opinion in Neurology, 2016, 29, 254-262.	3.6	51
84	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Human Molecular Genetics, 2016, 25, 308-316.	2.9	31
85	Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled â€“ MS arising during Tocilizumab therapy for rheumatoid arthritis. Multiple Sclerosis Journal, 2016, 22, 257-258.	3.0	6
86	Teriflunomide in Patients with Relapsingâ€“Remitting Forms of Multiple Sclerosis. CNS Drugs, 2016, 30, 41-51.	5.9	29
87	Cytokine profiles show heterogeneity of interferon-Î² response in multiple sclerosis patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e202.	6.0	34
88	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. Molecular and Cellular Proteomics, 2016, 15, 318-328.	3.8	28
89	PML risk stratification using anti-JCV antibody index and L-selectin. Multiple Sclerosis Journal, 2016, 22, 1048-1060.	3.0	62
90	Are Leberâ€™s mitochondial DNA mutations associated with aquaporin-4 autoimmunity?. Multiple Sclerosis Journal, 2016, 22, 393-394.	3.0	7

#	Article	IF	Citations
91	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	6.0	19
92	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. PLoS ONE, 2015, 10, e0134414.	2.5	5
93	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. Multiple Sclerosis Journal, 2015, 21, 1802-1810.	3.0	10
94	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
95	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643.	7.6	54
96	Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1498-1512.	3.0	8
97	Lipidâ€specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	5.3	48
98	NLRP3 inflammasome is associated with the response to IFN-Î² in patients with multiple sclerosis. Brain, 2015, 138, 644-652.	7.6	93
99	Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation-Induced Neurodegeneration. Stem Cells Translational Medicine, 2015, 4, 252-260.	3.3	20
100	Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. Clinical Immunology, 2015, 160, 133-141.	3.2	6
101	A functional variant that affects exon-skipping and protein expression ofSP140as genetic mechanism predisposing to multiple sclerosis. Human Molecular Genetics, 2015, 24, 5619-5627.	2.9	43
102	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
103	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis. Journal of Neuroimmunology, 2015, 278, 277-279.	2.3	15
104	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain, 2015, 138, 1863-1874.	7.6	403
105	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 48.	7.2	26
106	Genome-wide significant association with seven novel multiple sclerosis risk loci. Journal of Medical Genetics, 2015, 52, 848-855.	3.2	34
107	Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation. Journal of Neuroimmunology, 2015, 289, 12-20.	2.3	10
108	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. Journal of Neuroimmunology, 2015, 288, 98-101.	2.3	12

#	Article	IF	Citations
109	Interferon-beta affects mitochondrial activity in CD4⁺ lymphocytes: Implications for mechanism of action in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1262-1270.	3.0	10
110	Significant clinical worsening after natalizumab withdrawal: Predictive factors. Multiple Sclerosis Journal, 2015, 21, 780-785.	3.0	43
111	Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. Biomarkers in Medicine, 2014, 8, 653-661.	1.4	84
112	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Multiple Sclerosis Journal, 2014, 20, 577-587.	3.0	40
113	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e47.	6.0	11
114	DNA Vaccination Techniques. Methods in Molecular Biology, 2014, 1304, 39-50.	0.9	2
115	Ancient and Recent Selective Pressures Shaped Genetic Diversity at AIM2-Like Nucleic Acid Sensors. Genome Biology and Evolution, 2014, 6, 830-845.	2.5	28
116	N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. Journal of Neurology, 2014, 261, 2338-2343.	3.6	52
117	Validation of semaphorin 7A and ala-Î²-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. Journal of Neuroinflammation, 2014, 11, 181.	7.2	28
118	Evaluating the response to glatiramer acetate in relapsingâ€“remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis Journal, 2014, 20, 1602-1608.	3.0	36
119	A case of neuromyelitis optica harboring both anti-aquaporin-4 antibodies and a pathogenic mitochondrial DNA mutation for Leberâ€™s hereditary optic neuropathy: clinical commentary. Multiple Sclerosis Journal, 2014, 20, 261-261.	3.0	2
120	Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 56-59.	2.3	7
121	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nature Medicine, 2014, 20, 272-282.	30.7	141
122	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. Journal of Neuroimmunology, 2014, 272, 51-55.	2.3	8
123	Body fluid biomarkers in multiple sclerosis. Lancet Neurology, The, 2014, 13, 113-126.	10.2	204
124	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-Î² therapy in multiple sclerosis. Journal of Medical Genetics, 2014, 51, 395-400.	3.2	19
125	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. Autoimmunity, 2014, 47, 127-133.	2.6	17
126	Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene. American Journal of Pathology, 2014, 184, 2420-2429.	3.8	8

#	Article	IF	Citations
127	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology, 2014, 83, 1210-1216.	1.1	30
128	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 49-52.	2.3	2
129	Immunoglobulin <scp>M</scp> oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis. Annals of Neurology, 2014, 76, 231-240.	5.3	51
130	TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology, 2013, 80, 2010-2016.	1.1	28
131	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain, 2013, 136, 1778-1782.	7.6	60
132	Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2013, 255, 102-104.	2.3	1
133	Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. Journal of Neuroimmunology, 2013, 263, 152-154.	2.3	13
134	SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 524-531.	3.0	38
135	Roles of the ubiquitin peptidase <scp>USP</scp>18 in multiple sclerosis and the response to interferonâ€Î² treatment. European Journal of Neurology, 2013, 20, 1390-1397.	3.3	32
136	TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients. Journal of Neuroimmunology, 2013, 261, 146-148.	2.3	5
137	Cellular immune responses in multiple sclerosis patients treated with interferon-beta. Clinical and Experimental Immunology, 2013, 171, 243-246.	2.6	5
138	Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. American Journal of Human Genetics, 2013, 92, 854-865.	6.2	164
139	Identification of a functional variant in theKIF5A-CYP27B1-METTL1-FAM119Blocus associated with multiple sclerosis. Journal of Medical Genetics, 2013, 50, 25-33.	3.2	59
140	Genome-wide significant association ofANKRD55rs6859219 and multiple sclerosis risk. Journal of Medical Genetics, 2013, 50, 140-143.	3.2	34
141	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809.	3.0	133
142	Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta. PLoS ONE, 2013, 8, e60994.	2.5	27
143	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. PLoS ONE, 2013, 8, e82796.	2.5	23
144	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes. Multiple Sclerosis Journal, 2012, 18, 959-965.	3.0	28

#	Article	IF	Citations
145	Value of NMO-IgG determination at the time of presentation as CIS. Neurology, 2012, 78, 1608-1611.	1.1	16
146	EBV-specific immune responses in patients with multiple sclerosis responding to IFNÎ² therapy. Multiple Sclerosis Journal, 2012, 18, 605-609.	3.0	20
147	Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 983-990.	3.0	54
148	Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2012, 9, 139.	7.2	35
149	ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. Genes and Immunity, 2012, 13, 253-257.	4.1	44
150	A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes and Immunity, 2012, 13, 21-28.	4.1	56
151	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Multiple Sclerosis Journal, 2012, 18, 1193-1196.	3.0	19
152	DNA-based vaccines for multiple sclerosis: Current status and future directions. Clinical Immunology, 2012, 142, 76-83.	3.2	32
153	Immunopathogenesis of multiple sclerosis. Clinical Immunology, 2012, 142, 2-8.	3.2	128
154	Therapeutic strategies in multiple sclerosis. Clinical Immunology, 2012, 142, 1.	3.2	1
155	Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. Journal of Neuroimmunology, 2012, 245, 98-101.	2.3	9
156	Transcriptomics: mRNA and alternative splicing. Journal of Neuroimmunology, 2012, 248, 23-31.	2.3	51
157	New technologies for biomarker discovery in multiple sclerosis. Journal of Neuroimmunology, 2012, 248, 1.	2.3	3
158	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. European Journal of Neurology, 2012, 19, 899-904.	3.3	55
159	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
160	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Multiple Sclerosis International, 2011, 2011, 1-9.	0.8	52
161	Multiple sclerosis: current treatment algorithms. Current Opinion in Neurology, 2011, 24, 230-237.	3.6	65
162	Role of tumour necrosis factor (TNF)-Î± and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. Clinical and Experimental Immunology, 2011, 166, 338-345.	2.6	36

#	Article	IF	Citations
163	Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. Genes and Immunity, 2011, 12, 110-115.	4.1	36
164	Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonî² therapy in multiple sclerosis. Genes and Immunity, 2011, 12, 466-472.	4.1	34
165	Re: CASP8 in MS. Journal of Neuroimmunology, 2011, 230, 193-193.	2.3	0
166	Tumor necrosis factor alpha (TNF-Î±), anti-TNF-Î± and demyelination revisited: An ongoing story. Journal of Neuroimmunology, 2011, 234, 1-6.	2.3	109
167	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 2011, 239, 101-104.	2.3	18
168	Risk of multiple sclerosis in children with acute demyelination. Lancet Neurology, The, 2011, 10, 399-400.	10.2	0
169	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clinical Immunology, 2011, 141, 348-356.	3.2	72
170	Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine. Current Neurology and Neuroscience Reports, 2011, 11, 484-491.	4.2	43
171	Pharmacogenomics in neurology: Current state and future steps. Annals of Neurology, 2011, 70, 684-697.	5.3	33
172	Implication of the tollâ€like receptor 4 pathway in the response to interferonâ€Î²2 in multiple sclerosis. Annals of Neurology, 2011, 70, 634-645.	5.3	35
173	Decision tree based fuzzy classifier of magnetic resonance spectra from cerebrospinal fluid samples. Fuzzy Sets and Systems, 2011, 170, 43-63.	2.7	6
174	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain, 2011, 134, 693-703.	7.6	96
175	Correction: Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis. Journal of Immunology, 2011, 187, 1518-1521.	0.8	0
176	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 1421.	4.5	44
177	Search for Specific Biomarkers of IFNÎ² Bioactivity in Patients with Multiple Sclerosis. PLoS ONE, 2011, 6, e23634.	2.5	45
178	An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Revista De Neurologia, 2011, 52, 321-30.	7.8	6
179	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. Journal of Neurology, 2010, 257, 742-746.	3.6	19
180	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86

#	Article	IF	Citations
181	Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis. Journal of Neuroimmunology, 2010, 222, 70-75.	2.3	12
182	B cell expression of the inhibitory FcÎ³ receptor is unchanged in early MS. Journal of Neuroimmunology, 2010, 223, 135-137.	2.3	5
183	Orchestrating innate immune responses in multiple sclerosis: Molecular players. Journal of Neuroimmunology, 2010, 225, 5-12.	2.3	20
184	The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes and Immunity, 2010, 11, 439-445.	4.1	79
185	Short commentary on â€˜a consensus protocol for the standardization of cerebrospinal fluid collection and biobankingâ€™. Multiple Sclerosis Journal, 2010, 16, 129-132.	3.0	7
186	Brainstem lesions in clinically isolated syndromes. Neurology, 2010, 75, 1933-1938.	1.1	164
187	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.6	3
188	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. Multiple Sclerosis Journal, 2010, 16, 55-61.	3.0	54
189	Targeting dendritic cells to treat multiple sclerosis. Nature Reviews Neurology, 2010, 6, 499-507.	10.1	61
190	Single-Nucleotide Polymorphisms in Response to Interferon-Beta Therapy in Multiple Sclerosis. Journal of Interferon and Cytokine Research, 2010, 30, 727-732.	1.2	13
191	IFN-Î² pharmacogenomics in multiple sclerosis. Pharmacogenomics, 2010, 11, 1137-1148.	1.3	20
192	Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis. Journal of Immunology, 2010, 185, 5392-5404.	0.8	27
193	Antiviral immune response in patients with multiple sclerosis and healthy siblings. Multiple Sclerosis Journal, 2010, 16, 355-358.	3.0	15
194	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain, 2010, 133, 1082-1093.	7.6	240
195	Epsteinâ€“Barr virus and multiple sclerosis: causation or association?. Future Microbiology, 2010, 5, 1617-1619.	2.0	5
196	Elevated Epsteinâ€“Barr virusâ€encoded nuclear antigenâ€1 immune responses predict conversion to multiple sclerosis. Annals of Neurology, 2010, 67, 159-169.	5.3	181
197	Measures in the first year of therapy predict the response to interferon Î² in MS. Multiple Sclerosis Journal, 2009, 15, 848-853.	3.0	215
198	Predicting responders to therapies for multiple sclerosis. Nature Reviews Neurology, 2009, 5, 553-560.	10.1	114

#	Article	IF	Citations
199	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology, 2009, 73, 1914-1922.	1.1	653
200	A type I interferon signature in monocytes is associated with poor response to interferon-Î² in multiple sclerosis. Brain, 2009, 132, 3353-3365.	7.6	186
201	Genome-wide Scan of 500Â000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology, 2009, 66, 972-8.	4.5	104
202	United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics, 2009, 10, 885-894.	1.3	11
203	HLA class I and II alleles and response to treatment with interferon-beta in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2009, 210, 116-119.	2.3	33
204	Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis. Journal of Neuroimmunology, 2009, 213, 142-147.	2.3	20
205	Corrigendum to â€œHLA class I and II alleles and response to treatment with interferon-beta in relapsingâ€“remitting multiple sclerosisâ€•[J. Neuroimmunol. 210(2009)116â€“119]. Journal of Neuroimmunology, 2009, 214, 132.	2.3	0
206	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clinical Immunology, 2009, 130, 145-150.	3.2	41
207	Plasma chitotriosidase activity in multiple sclerosis. Clinical Immunology, 2009, 131, 216-222.	3.2	27
208	Reply: Plasma chitotriosidase activity in multiple sclerosis. Clinical Immunology, 2009, 133, 284.	3.2	0
209	Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. Clinical Immunology, 2009, 133, 364-374.	3.2	16
210	Plasma levels of 15dâ€PGJ₂ are not altered in multiple sclerosis. European Journal of Neurology, 2009, 16, 1197-1201.	3.3	7
211	Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. Journal of Neurology, 2008, 255, 1136-1141.	3.6	23
212	Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology, 2008, 65, 337-44.	4.5	154
213	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology, 2008, 70, 1079-1083.	1.1	317
214	Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 412-414.	3.0	6
215	Relationship between MRI lesion activity and response to IFN-Î² in relapsingâ€“remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2008, 14, 479-484.	3.0	104
216	Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. Therapy: Open Access in Clinical Medicine, 2008, 5, 623-629.	0.2	1

#	Article	IF	Citations
217	Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms. PLoS ONE, 2008, 3, e3490.	2.5	99
218	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. Multiple Sclerosis Journal, 2007, 13, 731-736.	3.0	6
219	Genomics in multiple sclerosisâ€"Current state and future directions. Journal of Neuroimmunology, 2007, 187, 1-8.	2.3	66
220	Neutralising antibodies to interferon Î² in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837.	3.6	48
221	TNFâ€"Î± converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. Journal of Neurology, 2006, 253, 701-706.	3.6	17
222	Altered maturation of circulating dendritic cells in primary progressive MS patients. Journal of Neuroimmunology, 2006, 175, 183-191.	2.3	37
223	Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. Journal of Neuroimmunology, 2006, 180, 147-158.	2.3	15
224	Defining the response to interferonâ€Î² in relapsingâ€remitting multiple sclerosis patients. Annals of Neurology, 2006, 59, 344-352.	5.3	295
225	Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology, 2006, 67, 968-972.	1.1	253
226	Plasma osteopontin levels in multiple sclerosis. Journal of Neuroimmunology, 2005, 158, 231-239.	2.3	171
227	Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. Journal of Neuroimmunology, 2005, 164, 140-147.	2.3	26
228	Is optic neuritis more benign than other first attacks in multiple sclerosis?. Annals of Neurology, 2005, 57, 210-215.	5.3	108
229	Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans. Bioinformatics, 2005, 21, ii180-ii181.	4.1	6
230	Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. Multiple Sclerosis Journal, 2004, 10, 618-620.	3.0	9
231	Decreased MMP-9 production in primary progressive multiple sclerosis patients. Multiple Sclerosis Journal, 2004, 10, 376-380.	3.0	20
232	Transcription-Based Prediction of Response to IFNÎ² Using Supervised Computational Methods. PLoS Biology, 2004, 3, e2.	5.6	144
233	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. Journal of Neuroimmunology, 2003, 143, 124-128.	2.3	35
234	C onversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fl uid and neurophysiological findings. Multiple Sclerosis Journal, 2003, 9, 39-43.	3.0	49

#	Article	IF	Citations
235	Interferon-Î² treatment alters peripheral blood monocytes chemokine production in MS patients. Journal of Neuroimmunology, 2002, 126, 205-212.	2.3	46
236	Assessment of different treatment failure criteria in a cohort of relapsingâ€“remitting multiple sclerosis patients treated with interferon Î²: Implications for clinical trials. Annals of Neurology, 2002, 52, 400-406.	5.3	114
237	Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: compound heterozygosity for the IVS2+1G-->A mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family. Annals of Neurology, 2001, 50, 108-12.	5.3	5
238	Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.. Journal of Clinical Investigation, 1998, 102, 671-678.	8.2	197